<DOC>
	<DOCNO>NCT00441922</DOCNO>
	<brief_summary>This trial compare efficacy docetaxel versus vinorelbine first-line treatment elderly patient advance NSCLC .</brief_summary>
	<brief_title>Trial Docetaxel Versus Vinorelbine 1st Line Treatment Elderly Patients With Non-Small-Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description>Docetaxel vinorelbine well know active agent treatment NSCLC . The standard treatment elderly patient advance NSCLC monotherapy third generation agent . The role comprehensive geriatric assessment treatment efficacy tolerance area investigation .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>Histologically cytologically confirm NonSmallCell Lung Cancer Stage IIIB/IV No prior chemotherapy Existence twodimensional measurable disease . The measurable disease irradiate Life expectancy 3 month Age ≥ 65 year Performance status ( WHO ) ≤ 3 Adequate bone marrow function ( absolute neutrophil count &gt; 1000/mm^3 , platelet count &gt; 100000/mm^3 , Hemoglobin &gt; 9 gr/mm^3 ) Adequate liver ( bilirubin &lt; 1.5 time upper limit normal SGOT/SGPT &lt; 2 time upper limit normal ) , renal function ( creatinine &lt; 2 mg/dl ) Informed consent Psychiatric illness social situation would preclude study compliance . Other concurrent uncontrolled illness Other invasive malignancy within past 5 year except nonmelanoma skin cancer No absence irradiate stable central nervous system metastatic disease . No presence reliable care giver Other concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Elderly</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>Docetaxel</keyword>
	<keyword>Vinorelbine</keyword>
</DOC>